What this Trial Is About

Researchers are evaluating a treatment approach for patients with p16-positive oropharynx cancer who have a favorable prognosis. This phase II, prospective study focuses on patients with either no lymph node involvement or malignant neck adenopathy limited to one side of the neck as confirmed by lymphoscintigraphy mapping. The study aims to assess outcomes including cancer progression on the opposite side of the neck within one year after radiation treatment. Participants will receive radiation therapy delivered on weekdays over either 6 or 7 weeks, totaling 35 treatment sessions. Some patients will also receive weekly doses of the drug cisplatin during the 7-week radiation schedule. The radiation targets only the affected side of the neck, guided by lymphoscintigraphy results. Treatment continues until completion, unacceptable side effects, or withdrawal of consent. During the study, participants will undergo assessments including PET/CT scans to monitor for cancer progression on the contralateral neck. Quality of life related to dry mouth symptoms will be measured at 6, 12, and 24 months using a standardized questionnaire. Researchers will also track disease-free and overall survival for up to 24 months following treatment. Patients remain on study treatment for 6 to 7 weeks, with ongoing monitoring after completion.

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer